BRCA1/2 testing among young women with breast cancer in Massachusetts, 2010–2013: An observational study using state cancer registry and All‐Payer claims data
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4648
Abstract: Testing for BRCA1/2 pathogenic variants is recommended for women aged ≤45 years with breast cancer. Some studies have found racial/ethnic and socioeconomic disparities in testing. We linked Massachusetts' All‐Payer Claims Database with Massachusetts Cancer Registry… read more here.
Keywords: cancer registry; payer claims; brca1 testing; breast cancer ... See more keywords
BRCA1/2 testing: therapeutic implications for breast cancer management
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0127-5
Abstract: Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed… read more here.
Keywords: cancer; platinum; brca1 testing; breast cancer ... See more keywords
Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "JCO clinical cancer informatics"
DOI: 10.1200/cci.22.00034
Abstract: PURPOSE Although BRCA1/2 testing in ovarian cancer improves outcomes, it is vastly underutilized. Scalable approaches are urgently needed to improve genomically guided care. METHODS We developed a Natural Language Processing (NLP) pipeline to extract electronic… read more here.
Keywords: patients ovarian; ovarian cancer; brca1 testing; nlp pipeline ... See more keywords
Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series
Sign Up to like & getrecommendations! Published in 2021 at "Diagnostics"
DOI: 10.3390/diagnostics11061046
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, with most patients diagnosed at advanced stages. First-line treatment based on a combined chemotherapy (FOLFIRINOX or gemcitabine plus nab-paclitaxel) provides limited benefits. Olaparib, a PARP inhibitor, has… read more here.
Keywords: pancreatic tumor; brca1 testing; tumor tissues; testing formalin ... See more keywords